GLPG-0634
- Filgotinib
- Soluble in DMSO
- MF: C21H23N5O3S
- MW: 425.5
Description
GLPG-0634 is the first orally-available, selective inhibitor of JAK1. In vitro, it selectively inhibits JAK1 and JAK2 with IC50 values of 10 nM and 28 nM, respectively, selective over JAK3 and TYK2 (IC50 Values of 810 nM and 116 nM, respectively), and a panel of 150 other kinases. However, when tested in vivo it selectively inhibits JAK1, displaying a 30-fold potency over JAK2.
More Information
| Parent CAS No. | 1206161-97-8 |
|---|---|
| Chemical Name | N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | C1C=C(C2=CC=CC3=NC(NC(C4CC4)=O)=NN23)C=CC=1CN1CCS(=O)(=O)CC1 |
| MFCD | N.A. |
| InChi | InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27) |
| InChiKey | RIJLVEAXPNLDTC-UHFFFAOYSA-N |
| CID | 49831257 |
| Short Description | JAK1 inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1338 | CP 690550 |
From $66.00 |
| 1378 | AG 490 |
From $71.50 |
| 1588 | TG 101348 |
From $88.00 |
| 1598 | Ruxolitinib |
From $71.50 |
| 1681 | Momelotinib |
From $88.00 |
| 1778 | AZ 960 |
From $104.50 |
| 1843 | JAK2 inhibitor 13 |
From $121.00 |
| 1955 | Baricitinib |
From $77.00 |
| 2072 | Tofacitinib citrate |
From $126.50 |
| 2217 | PF 956980 |
From $99.00 |
| 2219 | AT 9283 |
From $99.00 |
| 2231 | XL 019 |
From $110.00 |
| 2316 | WP 1066 |
From $104.50 |
| 2539 | Solcitinib |
From $99.00 |
| 2554 | LY 2784544 |
From $104.50 |
| 2775 | Cerdulatinib |
From $93.50 |
| 2792 | NVP-BSK805 |
From $137.50 |
| 3671 | CEP-33779 |
From $104.50 |
| 3813 | BMS-911543 |
From Inquiry |
| 3855 | AZD-4205 |
From Inquiry |
| 3861 | Decernotinib |
From Inquiry |
| 4091 | Deucravacitinib |
From $165.00 |
| 4124 | Momelotinib hydrochloride |
From $132.00 |
| 4263 | ABBV-467 |
From Inquiry |
